A robotic puppy with a 23,000-name waitlist raised $7M to start shipping
Tombot raised $7M to ship Jennie, its robotic puppy, to a 23,000-name waitlist, an elder-care play built on the pet bond.
The interesting number in Tombot's raise is not the $7 million. It is the 23,000 people who put down their names for a robotic Labrador before the first unit shipped. That waitlist is the asset, and the financing exists to turn it into revenue by fall.
Tombot closes a $7M Series A3 to move from development to shipping
The companion-robotics maker closed a $7 million Series A3 growth round. Investors include Caduceus Capital Partners, Wavemaker 360, the Lutheran Foundation for Long Term Living, and Florida Community Health Network.
The money funds the transition from product development to commercial scale: manufacturing, operations, and a planned first customer shipment in fall 2026.
Tombot's product, Jennie, is a robotic puppy built to mimic the movement and responses of an 8-to-10-week-old Labrador. It is aimed at older adults and people managing anxiety, loneliness, autism, or PTSD who cannot care for a live animal.
The company reports more than 23,000 pre-order and waitlist customers. Founder and chief executive Tom Stevens, who has spent more than 35 years across healthcare robotics, AI, and the pet industry, framed the round as the bridge from building to selling. The idea traces back to his own mother's experience.
Why the investor mix matters more than the round size
Look at who wrote the checks. This is not a consumer-gadget syndicate. Caduceus and Wavemaker 360 are healthcare-focused, and the other two backers are long-term-care and community-health institutions. That tells you what Tombot actually is.
This is a healthcare play wearing a pet-industry costume
Jennie competes less with toys and more with companionship interventions in elder care, memory care, and behavioral health. The backers are positioning it for institutional channels, senior living, and aging-in-place, where reimbursement and bulk purchasing live.
A 23,000-name waitlist de-risks the launch and tells you about demand
Pre-orders at this scale are rare validation for hardware, which usually struggles to prove appetite before tooling. It also explains a $7 million round that is sized to manufacture and ship, not to keep searching for product-market fit.
The pet-adjacent framing is a wedge, not the market
The lesson for operators: the companionship value of pets is being unbundled from live animals. That opens categories live pets cannot serve, from allergy and mobility constraints to facilities that ban animals. The emotional job-to-be-done travels even when the dog does not.
The risk is the oldest one in hardware. A waitlist is not a sale, and manufacturing at scale has killed more well-funded robotics companies than weak demand ever did. Fall shipping is the moment the 23,000 names either convert or churn.
Whether the fall launch converts the waitlist into a business
The next two quarters are the whole test. Watch three things.
Conversion: how many of the 23,000 actually buy when invoiced, and at what price point. That ratio is the real demand signal.
Channel: whether Tombot sells direct to consumers, into senior-living and care facilities, or both. The institutional path is slower but stickier and points back to its healthcare investors.
Unit economics: robotic hardware lives or dies on bill-of-materials and returns. A companion device that disappoints emotionally gets sent back fast.
Ship dates slip. If Tombot hits fall and converts even a fraction of its waitlist, it proves a category thesis worth watching: companionship as a product, sold on the strength of the bond pets created.
Other News
More stories shaping the pet industry this week. From funding rounds and product launches to regulatory shifts and retail strategy, stay ahead of what's driving the market.
Years Recalls Nearly All Its Fresh Meals After 192 Dog Eye Injury Reports
Years, a UK subscription fresh dog food brand, recalled nearly its entire meal lineup after 192 customers reported dogs developing sudden dry eye. The recall lands two months after a nationwide Pets at Home rollout and a growth round from Verlinvest and Five Seasons Ventures meant to fund further expansion.
ZymIQ's US Patent Bets on Enzymes Over Antimicrobials in Pet Care
ZymIQ Technology AB has patented the enzyme-based, biofilm-targeting technology behind its Kalzyme pet dental, dermal and ear care line in the US. The bigger pattern: enzyme mechanisms challenging the broad-spectrum antimicrobials that still dominate preventive pet care.
StoneX Acquires the Merchandiser Behind Pet Food's Protein Supply
StoneX Group has acquired Advanced Marketing Group, a merchandiser of animal protein-based feed ingredients that serves pet food manufacturers, dairy and poultry producers, and feedlots. Terms weren't disclosed, but the deal folds a key ingredient supplier into a much larger commodities-trading balance sheet.